RESEARCH TRIANGLE PARK, N.C. , July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced the closing of its

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, will host a webcast and

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced the pricing of an

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced today that it has

Acquisition Bolsters Liquidia’s Capabilities in Pulmonary Arterial Hypertension (PAH) and Commercial Readiness for LIQ861, if Approved Two New Directors, - Roger Jeffs , Ph.D. and Paul Manning , to Join Board Concurrent with Acquisition Close RESEARCH TRIANGLE PARK, N.C.

RESEARCH TRIANGLE PARK, N.C. , June 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United

RESEARCH TRIANGLE PARK, N.C. , May 27, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT ® technology, today announced that Neal

RESEARCH TRIANGLE PARK, N.C. , May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT ® technology, today announced the

Received FDA Acceptance of LIQ861 NDA for Review Reported Final Safety and Tolerability Results for LIQ861 Inspire Trial Management to Host Webcast and Conference Call Today at 4:30p.m. ET RESEARCH TRIANGLE PARK, N.C. , May 11, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.

RESEARCH TRIANGLE PARK, N.C. , May 06, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ® technology, today announced that first quarter